

Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CF206C0807E8EN.html>

Date: March 2022

Pages: 85

Price: US\$ 2,000.00 (Single User License)

ID: CF206C0807E8EN

Abstracts

Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 7 and 14 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in
Therapeutics Development

Accure Therapeutics SL

Astellas Pharma Inc

AstraZeneca Plc

Atai Life Sciences NV

Autifony Therapeutics Ltd

Biogen Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Coronis NeuroSciences Ltd

Cyclerion Therapeutics Inc

EuMentis Therapeutics Inc

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Monument Therapeutics Ltd

Neurocrine Biosciences Inc

Novartis AG

Pfizer Inc

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Suven Life Sciences Ltd

Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles

ACT-02 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ASP-5736 - Drug Profile

Product Description

Mechanism Of Action

AUT-1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AUT-6 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AUT-9 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

basmisanil - Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-425809 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-474121 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-955829 - Drug Profile

Product Description

Mechanism Of Action
CAD-8688 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAD-9303 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CP-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CY-6463 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EM-036 - Drug Profile
Product Description
Mechanism Of Action
Iuvadaxistat - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-4334 - Drug Profile
Product Description
Mechanism Of Action
NBI-1065846 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pesampator - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
RL-007 - Drug Profile

Product Description

Mechanism Of Action

History of Events

samelisant - Drug Profile

Product Description

Mechanism Of Action

History of Events

SKL-20540 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Cognitive Impairment Associated With Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit COMT for Cognitive Impairment Associated with Schizophrenia (CIAS) and Unspecified Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

SP-14040 - Drug Profile

Product Description

Mechanism Of Action

SUVND-4010 - Drug Profile

Product Description

Mechanism Of Action

VQW-765 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VU-0467154 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones

Featured News & Press Releases

Dec 14, 2021: atai Life Sciences announces successful outcome of phase 2a biomarker trial of RL-007 in cognitive impairment associated with schizophrenia

May 27, 2021: Cycleron Therapeutics announces publication of CY6463 preclinical data in frontiers in pharmacology

May 24, 2021: Boehringer Ingelheim's investigational treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

Apr 27, 2021: Cycleron Therapeutics hosted webinar to discuss pipeline progress, provides update on CY6463 clinical program

Apr 20, 2021: Cycleron Therapeutics to host pipeline update webinar

Mar 02, 2021: Neurocrine Biosciences announces top-line results from phase II interact study evaluating Luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with Schizophrenia (CIAS)

Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboraci?n" grant

Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Accure Therapeutics SL, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Atai Life Sciences NV, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Autifony Therapeutics Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim International GmbH, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cycleron Therapeutics Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by EuMentis Therapeutics Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Merck & Co

Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Monument Therapeutics Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neurocrine Biosciences Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Novartis AG, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2022 (Contd..1)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CF206C0807E8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF206C0807E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

